This is a Special Purpose Acquisition Company (SPAC), a blank check company incorporated in the Cayman Islands in 2024 with no operating business. The SPAC raised approximately $210M through its IPO, with proceeds held in a trust account, and its sole purpose is to identify and acquire a private company in the healthcare or healthcare-adjacent space, taking it public through a merger. Target areas include life sciences, medical devices, diagnostics, value-based care, digital healthcare, and mental health services, with target enterprise values between $160M and $2B. The SPAC has 24 months from IPO close to complete an acquisition, extendable to 36 months with shareholder approval; if no deal closes, the trust is liquidated and public shareholders receive back roughly $10.00 per share. The sponsor receives founder shares — typically 20% of post-IPO shares at nominal cost — that are worthless if no deal closes but can be highly valuable upon deal completion, creating an incentive to close a deal that may not always align with public shareholder interests. Public shareholders retain redemption rights, allowing them to redeem shares for their pro-rata trust value at the time of any deal vote, while warrants provide upside if the post-merger company's stock appreciates. The management team argues its differentiation lies in its healthcare industry network and operating experience, though it acknowledges that a prior SPAC vehicle, Altitude Acquisition Corp, was delisted from Nasdaq without completing a transaction.